Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

October 12, 2018

Primary Completion Date

October 21, 2026

Study Completion Date

October 21, 2026

Conditions
Fallopian Tube Endometrioid AdenocarcinomaFallopian Tube High Grade Serous AdenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian High Grade Serous AdenocarcinomaPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaPrimary Peritoneal High Grade Serous Adenocarcinoma
Interventions
BIOLOGICAL

Anetumab Ravtansine

Given IV

BIOLOGICAL

Bevacizumab

Given IV

DRUG

Paclitaxel

Given IV

Trial Locations (23)

22908

University of Virginia Cancer Center, Charlottesville

33136

University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami

33146

UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables

33324

UM Sylvester Comprehensive Cancer Center at Plantation, Plantation

33442

UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach

33612

Moffitt Cancer Center, Tampa

37232

Vanderbilt University/Ingram Cancer Center, Nashville

43210

Ohio State University Comprehensive Cancer Center, Columbus

48201

Wayne State University/Karmanos Cancer Institute, Detroit

48334

Weisberg Cancer Treatment Center, Farmington Hills

53792

University of Wisconsin Carbone Cancer Center - University Hospital, Madison

60611

Northwestern University, Chicago

63110

Washington University School of Medicine, St Louis

66061

The University of Kansas Cancer Center - Olathe, Olathe

66205

University of Kansas Hospital-Westwood Cancer Center, Westwood

66606

University of Kansas Health System Saint Francis Campus, Topeka

66762

Mercy Hospital Pittsburg, Pittsburg

67401

Salina Regional Health Center, Salina

67601

HaysMed, Hays

80045

UCHealth University of Colorado Hospital, Aurora

92868

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

M5G 2M9

University Health Network-Princess Margaret Hospital, Toronto

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT03587311 - Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Biotech Hunter | Biotech Hunter